PD173074 Licensed by Pfizer

Catalog No.S1264

PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.

Price Stock Quantity  
USD 98 In stock
USD 70 In stock
USD 120 In stock
USD 470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

PD173074 Chemical Structure

PD173074 Chemical Structure
Molecular Weight: 523.67

Validation & Quality Control

6 customer reviews :

Quality Control & MSDS

Related Compound Libraries

FGFR Inhibitors with Unique Features

  • Pan FGFR Inhibitor

    BGJ398 (NVP-BGJ398) FGFR1/2/3-selective, IC50=0.9 nM/1.4 nM/1 nM.

  • Most Potent FGFR Inhibitor

    AZD4547 FGFR1, IC50=0.2 nM; FGFR2, IC50=2.5 nM; FGFR3, IC50=1.8 nM.

  • FDA-approved FGFR Inhibitor

    Ponatinib (AP24534) Approved by FDA for resistant or intolerant CML and Ph+ ALL.

  • Newest FGFR Inhibitor

    SSR128129E Orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.

Product Information

  • Compare FGFR Inhibitors
    Compare FGFR Products
  • Research Area
  • Inhibition Profile
  • PD173074 Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.
Targets FGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
c-Src [1]
(Cell-free assay)
EGFR [1]
(Cell-free assay)

 View  More

IC50 ~25 nM 100 nM-200 nM 19.8 μM >50 μM
In vitro PD173074 is an ATP-competitive inhibitor of FGFR1 with Ki of ~40 nM. PD173074 is also an effective inhibitor of VEGFR2. Compared to FGFR1, PD173074 weakly inhibits the activities of Src, InsR, EGFR, PDGFR, MEK, and PKC with 1000-fold or greater IC50 values. PD173074 inhibits autophosphorylation of FGFR1 and VEGFR2 in a dose-dependent manner with IC50 of 1-5 nM and 100-200 nM, respectively. [1] PD173074 inhibits FGF-2 promotion of granule neuron survival in a dose-dependent manner with IC50 of 12 nM, exhibiting 1,000-fold greater potency than that of SU 5402. [2] PD173074 specifically inhibits FGF-2-mediated effects on proliferation, differentiation, and MAPK activation in oligodendrocyte (OL) lineage cells. [3] PD173074 is active against the WT receptor and FGFR3 mutations in multiple myeloma (MM) cell lines. PD173074 also potently inhibits autophosphorylation of FGFR3 in a dose-dependent manner with IC50 of ~5 nM. PD173074 treatment potently reduces viability of FGFR3-expressing KMS11 and KMS18 cells with IC50 of <20 nM. Inhibition of aFGF-stimulated MM cell growth by PD173074 is highly correlated with the expression of FGFR3. PD173074 treatment completely abolishes NIH 3T3 transformation mediated by Y373C FGFR3 but not by Ras V12, demonstrating that PD173074 specifically targets FGFR3-mediated cell transformation and lacks nonspecific cytotoxic effect. PD173074 also induces functional maturation of KMS11 and KMS18 cells. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
NCI-H1581NYS0[mpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{PJbmlEPTB;MD6wNVIzPSEQvF2=MlLRV2FPT0WU
KG-1Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEm3SI9KSzVyPUCuNFUyOjlizszNNHfnfY1USU6JRWK=
MFM-223NETlN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\rU2lEPTB;MD6yNVU4PiEQvF2=NUH6Z5RpW0GQR1XS
EoL-1-cellNXe1Zlk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVLJR|UxRTBwM{K5PFQh|ryPMnrkV2FPT0WU
ECC10M4nUOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTBwM{O4PVgh|ryPNV[wVHVrW0GQR1XS
H-EMC-SSMm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmHsTWM2OD1yLkO0O|E2KM7:TR?=MYfTRW5ITVJ?
AN3-CANXHVS49ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTBwNECxN|Mh|ryPNX\MNVB5W0GQR1XS
HuO-3N1M{C0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1G2XmlEPTB;MD61OFY2OyEQvF2=NI\pcYVUSU6JRWK=
RT-112MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGq2SmpKSzVyPUCuOVQ4ODFizszNMYHTRW5ITVJ?
NEC8M{D0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEDBeZhKSzVyPUCuOVYzQDlizszNM{XhVnNCVkeHUh?=
D-263MGM2nQNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVz0e5pIUUN3ME2wMlcyOTV7IN88US=>NIP6eItUSU6JRWK=
SW962MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUfVd|NMUUN3ME2wMlc5QTh6IN88US=>M3HNNHNCVkeHUh?=
BV-173MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3vkOmlEPTB;MD64OFYzOyEQvF2=MoXBV2FPT0WU
MFE-280NULGNIZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\KTWM2OD1yLki1PFczKM7:TR?=NVT1cVd4W0GQR1XS
HuH-7MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1raR2lEPTB;MT6yOFQ3PCEQvF2=NEjyPJJUSU6JRWK=
RS4-11NYnveFdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTFwM{O4PFYh|ryPMkHiV2FPT0WU
DMS-114M2jhSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTFwM{[3N|ch|ryPMlXBV2FPT0WU
MSTO-211HNV3jZmx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTFwNEezO|gh|ryPMkXXV2FPT0WU
DU-145MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEXRN|FKSzVyPUGuOVgzOTdizszNMn6zV2FPT0WU
A172MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\JO5d2UUN3ME2xMlcxOzV3IN88US=>NHf3[pRUSU6JRWK=
SBC-1MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTJwMEm0JO69VQ>?M2XCfnNCVkeHUh?=
H9MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTJwMUSzNFYh|ryPNGDwdYRUSU6JRWK=
NCI-SNU-1MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGLkPWRKSzVyPUKuNVg{QTRizszNNHLIT5dUSU6JRWK=
NCI-H720NXWwNmdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTJwMkGyPFMh|ryPMmThV2FPT0WU
HCC2218NHv6R4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoHyTWM2OD1{LkO3PVM6KM7:TR?=M{jEcnNCVkeHUh?=
G-401MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRTJwNEexPFkh|ryPNIDjVoNUSU6JRWK=
MPP-89NGTkfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\zd2lEPTB;Mj60PFM3PCEQvF2=MoO3V2FPT0WU
697M4rFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUjaRXlzUUN3ME2yMlY2OzNzIN88US=>Mk[1V2FPT0WU
KARPAS-45Mn3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmjGTWM2OD1{LkewO|Q4KM7:TR?=MoL2V2FPT0WU
MG-63MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHG3TIdKSzVyPUKuPVQzPjJizszNMXPTRW5ITVJ?
NTERA-S-cl-D1MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;3WWlEPTB;Mz6wN|Q4OiEQvF2=NHPJdGVUSU6JRWK=
G-402MkfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH3Vd|FKSzVyPUOuNVI4OjdizszNNI\lSoVUSU6JRWK=
NKM-1MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\KdGRKSzVyPUOuNVM2PjRizszNMYHTRW5ITVJ?
RH-18M1nTOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTNwMUm1PVgh|ryPNF\zR2JUSU6JRWK=
NCI-H1092NUfRZVJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnGxTWM2OD1|LkG5Olkh|ryPM4fXXnNCVkeHUh?=
RPMI-8226NXjZPYdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{PtTmlEPTB;Mz6yN|Q1PyEQvF2=MmXEV2FPT0WU
GAMGMlHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUDIfZlKUUN3ME2zMlQ3PTd4IN88US=>NU\sbWFtW0GQR1XS
HHNHP4cWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLuPYlKSzVyPUOuOFc3PzZizszNM2jTeXNCVkeHUh?=
RO82-W-1M3W2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGTTdIpKSzVyPUOuOFk5PTVizszNNEDEWZhUSU6JRWK=
CCRF-CEMNHPHe5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUntW4UxUUN3ME2zMlUxPDh6IN88US=>MnzaV2FPT0WU
NBsusSRMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETh[nlKSzVyPUOuOlM6PjlizszNMm\YV2FPT0WU
CHL-1NF7YZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFTle5hKSzVyPUOuOlU4QTlizszNMlHLV2FPT0WU
LK-2M2SyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7Gc41kUUN3ME2zMlY4OTN|IN88US=>Mnj2V2FPT0WU
Hs-578-TMnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlrXTWM2OD1|Lk[3PFc{KM7:TR?=M3mzdnNCVkeHUh?=
CTB-1NFHidZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTNwOECwOVEh|ryPM2rI[HNCVkeHUh?=
ES5MniwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\5TVdKSzVyPUOuPFM3OzdizszNNVPNVoExW0GQR1XS
A204MmnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4jVOGlEPTB;Mz65NlA4PSEQvF2=NU\6TpRNW0GQR1XS
SW780M{DhUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NICzSGxKSzVyPUOuPVIzPDVizszNNEXKXlhUSU6JRWK=
EW-3NV\MSZdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4C0XmlEPTB;Mz65PFkzOyEQvF2=MWTTRW5ITVJ?
A704NUDwT3VuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\SRWlEPTB;ND6yPFczOyEQvF2=MmDQV2FPT0WU
LU-139MnO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYLQRXU{UUN3ME20MlMyPTN2IN88US=>NUKzNXQyW0GQR1XS
CAL-72MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTRwNEG3OFYh|ryPNHvadpRUSU6JRWK=
D-336MGNVezZZlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPKTWM2OD12LkS2PFE4KM7:TR?=NHjTTIJUSU6JRWK=
LAMA-84NIi0OZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVnnTWNGUUN3ME20MlU{OzFizszNM3LmcnNCVkeHUh?=
GI-ME-NM1j5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUjBXIk6UUN3ME20MlU1QDFizszNNV32OotXW0GQR1XS
KM-H2Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjDSoZKSzVyPUSuOVUzOjJizszNMY\TRW5ITVJ?
NCI-H209MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\rTWM2OD12LkW4Nlg{KM7:TR?=NF\uXWhUSU6JRWK=
IGROV-1NHL0dFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3u1SGlEPTB;ND64O|E3QCEQvF2=Mk\aV2FPT0WU
L-363M2\jO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFexW49KSzVyPUSuPVY3PjVizszNMXnTRW5ITVJ?
SK-MEL-3M3f1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3TIRmlEPTB;NT6yOFA3KM7:TR?=M{jzR3NCVkeHUh?=
HuO9MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXfQcWlwUUN3ME21MlM5QDR|IN88US=>MmrnV2FPT0WU
NOS-1Mn7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFfMSGtKSzVyPUWuO|I6OjdizszNM2nXR3NCVkeHUh?=
NCI-H1770M1rFS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTVwOUWwN|Ih|ryPMUjTRW5ITVJ?
SF126NH7hWFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mlr4TWM2OD14LkKxOFA3KM7:TR?=NH\zO3FUSU6JRWK=
ML-2NU\OdHZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnITY5DUUN3ME22MlI1QTd5IN88US=>MVjTRW5ITVJ?
CHP-134MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2rZXGlEPTB;Nj6yOVE5OiEQvF2=NGTTPIVUSU6JRWK=
NCI-H1355MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTZwNEG3N|Mh|ryPM2\NbXNCVkeHUh?=
TE-12NX;uTZN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfJNJJKSzVyPU[uO|I3PzFizszNNXvpd4JPW0GQR1XS
A4-FukNX36bXU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NETXO4pKSzVyPU[uO|MyPDJizszNMm\XV2FPT0WU
MV-4-11M4HvO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYTxT5c{UUN3ME22Mlc3PjJ4IN88US=>M2XQUXNCVkeHUh?=
SK-UT-1NFri[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlewTWM2OD14LkmxO|g1KM7:TR?=MlrhV2FPT0WU
J-RT3-T3-5MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3OSFNKSzVyPUeuNFc4PjRizszNNWPBfW1YW0GQR1XS
ME-180M3jmO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUPJR|UxRTdwMUC0NFQh|ryPMkjpV2FPT0WU
SK-MEL-28NILFfWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEXlSnZKSzVyPUeuN|c5OTlizszNNUHkZYlzW0GQR1XS
HAL-01MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTdwNEizOFEh|ryPMk\LV2FPT0WU
ES8MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2[4SGlEPTB;Nz62PVYzPiEQvF2=NVHidXdIW0GQR1XS
DBNUfXfY1rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{Dy[2lEPTB;OD6xNVUxPCEQvF2=MmS3V2FPT0WU
SK-NEP-1M4PNZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXXRfG1uUUN3ME24MlQ5OTR7IN88US=>MX7TRW5ITVJ?
COR-L88MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVrGdotKUUN3ME24MlUxQThzIN88US=>Mkn6V2FPT0WU
LB1047-RCCNFTLcYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M13p[2lEPTB;OD61NlIyOiEQvF2=MYjTRW5ITVJ?
NCI-H520MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRThwNkKxOVch|ryPMXrTRW5ITVJ?
SW954M2fKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPpSnd5UUN3ME24MlY6Pzh4IN88US=>Mn;zV2FPT0WU
TE-6MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRThwN{WxOFMh|ryPMkXOV2FPT0WU
D-283MEDNIryWmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7W[lBCUUN3ME25MlA3PTN2IN88US=>NVPwclFjW0GQR1XS
DBTRG-05MGNG\xfJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\TNmlEPTB;OT6wPVYxPyEQvF2=M3\n[HNCVkeHUh?=
NCI-H446NVHRcFJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{TEOmlEPTB;OT6yPVUzPiEQvF2=NIPUUnFUSU6JRWK=
HOSMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\HTWM2OD17LkO1NVM1KM7:TR?=NFPkXWxUSU6JRWK=
ES4MnrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTlwNUC1PVUh|ryPMUPTRW5ITVJ?
EW-13NUX0VYpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlToTWM2OD17Lki5NFU2KM7:TR?=MWHTRW5ITVJ?
IST-MES1M1vZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M13XWGlEPTB;OT65OFU{PCEQvF2=MWXTRW5ITVJ?
CAS-1MmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1y0VmlEPTB;OT65O|Y2QSEQvF2=MnfmV2FPT0WU
EM-2MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTFyLkGzPVMh|ryPNWfUbYFxW0GQR1XS
SW948Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH7hPHNKSzVyPUGwMlE5QDJizszNMoHDV2FPT0WU
OAW-42MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlfnTWM2OD1zMD61NlY4KM7:TR?=NYrD[G86W0GQR1XS
BE-13MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH;RZZpKSzVyPUGwMlY2PzZizszNNHfkXFFUSU6JRWK=
KU812NVS0SWxkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;RemlEPTB;MUCuO|M6OSEQvF2=NGLlUnpUSU6JRWK=
SK-MEL-30MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWDIOmo3UUN3ME2xNE45QTBzIN88US=>NVvDZ|F7W0GQR1XS
A2780NF;qXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlXETWM2OD1zMT6wN|A5KM7:TR?=MonsV2FPT0WU
TGBC24TKBMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUf5cFYyUUN3ME2xNU4xPzN5IN88US=>M1zoOXNCVkeHUh?=
GOTOMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnfjTWM2OD1zMT6yNFg1KM7:TR?=MWfTRW5ITVJ?
NCI-H526NVu3XpJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfTTWM2OD1zMT6zPFM4KM7:TR?=MWLTRW5ITVJ?
BHT-101MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnn5TWM2OD1zMT60OFU3KM7:TR?=NWHMe4M{W0GQR1XS
NCI-H1155MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH3GW5JKSzVyPUGxMlQ6PDdizszNNUXRd2FUW0GQR1XS
MCF7NYG0V3lzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFjlRmZKSzVyPUGxMlYyPjdizszNMmj0V2FPT0WU
MKN45NHrvdIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX3JR|UxRTFzLke5PVMh|ryPMXHTRW5ITVJ?
MOLT-16NWfZdHQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1TvXGlEPTB;MUGuPVY6OiEQvF2=M2LKcXNCVkeHUh?=
YH-13NIrKdI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnFWpVKSzVyPUGyMlA{PDZizszNM1j6XnNCVkeHUh?=
P12-ICHIKAWANE[yNIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXrJdFdWUUN3ME2xNk4{QDR3IN88US=>NVjFfWhrW0GQR1XS
GR-STMm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3zJbGlEPTB;MUKuOVI6PSEQvF2=MUHTRW5ITVJ?
CAKI-1Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXKOWJKSzVyPUGyMlc6OSEQvF2=NF3TXW1USU6JRWK=
LXF-289NHXtZWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVzRfJRGUUN3ME2xN{4xQDN3IN88US=>MUTTRW5ITVJ?
MHH-PREB-1M2K0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTF|LkK3NFQh|ryPMoLrV2FPT0WU
EW-16M{LPPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnlW5J7UUN3ME2xN{4{OTh5IN88US=>M4\DOnNCVkeHUh?=
NCI-H82MoDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTF|LkSxPVUh|ryPMXnTRW5ITVJ?
MMAC-SFNVG2WYUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnnXTWM2OD1zMz60OVQ4KM7:TR?=NIradGtUSU6JRWK=
COLO-684MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX7ZcJE3UUN3ME2xN{42OzF6IN88US=>NUX4VIZ3W0GQR1XS
QIMR-WILNFPDXnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XUNGlEPTB;MUOuPFExQSEQvF2=MW\TRW5ITVJ?
NB69NIHYUGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFroZYVKSzVyPUGzMlk5PjhizszNMWfTRW5ITVJ?
NCI-H2291MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTsTWM2OD1zND60OFU{KM7:TR?=NXf6c5pmW0GQR1XS
MKN7NWS4XGNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXq4TIM6UUN3ME2xOE43Pjd4IN88US=>MnroV2FPT0WU
HDLM-2NV3FNIszT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFXFOG9KSzVyPUG1MlEzQDZizszNMkG5V2FPT0WU
A253M2TibWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XicGlEPTB;MUWuN|g3QSEQvF2=NXnPbIRRW0GQR1XS
SK-LU-1NES2ZYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlT5TWM2OD1zNT65NFk1KM7:TR?=MWfTRW5ITVJ?
MEG-01MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIW1VnhKSzVyPUG1MlkyODdizszNNVHzSZJGW0GQR1XS
SK-N-DZNXvNfmFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLoO24xUUN3ME2xOU46Ozd4IN88US=>Mkn6V2FPT0WU
H4MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF[3WGRKSzVyPUG2MlA5QCEQvF2=MWfTRW5ITVJ?
LU-65NWPUdnh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1jzT2lEPTB;MU[uN|M5PCEQvF2=NXrxW2NmW0GQR1XS
NCI-H1048Mm\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33semlEPTB;MU[uOVE3PSEQvF2=MkSzV2FPT0WU
LCLC-97TM1MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTF4LkW4PFkh|ryPNWXTcFhiW0GQR1XS
CAL-120MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWrCSoRPUUN3ME2xOk46QDd7IN88US=>NH3mXlhUSU6JRWK=
LU-134-AM{W1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlHpTWM2OD1zNz6zN|kyKM7:TR?=NGf1dlRUSU6JRWK=
SK-MEL-1MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjLTWM2OD1zNz63NVI4KM7:TR?=MmTMV2FPT0WU
NCI-H69NYfQXG52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLrU3JEUUN3ME2xO{46OzB5IN88US=>NVHhUFhuW0GQR1XS
MC116MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnzTTWM2OD1zNz65O|Uh|ryPNGX4W4JUSU6JRWK=
UMC-11MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3fDbWlEPTB;MUiuNVc5QCEQvF2=MnXLV2FPT0WU
HCC1395NYL0ZoVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{Pre2lEPTB;MUiuOFMxOSEQvF2=NFHueZdUSU6JRWK=
no-10Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\CbW5KSzVyPUG4MlY{QDhizszNNXzNeYg4W0GQR1XS
NYNFrKUYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlrrTWM2OD1zOT6wPFA6KM7:TR?=NHrNe41USU6JRWK=
OS-RC-2MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M362OGlEPTB;MUmuNVI2OiEQvF2=MknIV2FPT0WU
D-423MGNETHNZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTF7LkO5OVIh|ryPNH3DT|hUSU6JRWK=
LC-2-adMkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfaTWM2OD1zOT63OlEzKM7:TR?=M1j3VHNCVkeHUh?=
DU-4475NVTZSJFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3y3fmlEPTB;MUmuPFg2OiEQvF2=M4D6OnNCVkeHUh?=
YKG-1M4izZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEfj[pBKSzVyPUG5Mlk3OiEQvF2=MlmxV2FPT0WU
HCC1569NF:1eFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWPiTZN5UUN3ME2yNE4zPjJ2IN88US=>MmnrV2FPT0WU
TYK-nuM2n6e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkHVTWM2OD1{MD6yPFQ4KM7:TR?=MVLTRW5ITVJ?
DELMkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTJyLkm4NFgh|ryPMXfTRW5ITVJ?
MHH-ES-1MlXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmjCTWM2OD1{MT6zOVk4KM7:TR?=M1:0ZnNCVkeHUh?=
KARPAS-299NHf4[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHvielFKSzVyPUKxMlUzQSEQvF2=NXnoXnRpW0GQR1XS
CTV-1MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlzWTWM2OD1{MT62NVczKM7:TR?=NFLJNW1USU6JRWK=
NCI-H2452M4TMWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3fHTmlEPTB;MkKuOlY4PyEQvF2=MYPTRW5ITVJ?
D-566MGNGr0RpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXPTWM2OD1{Mj63OlAyKM7:TR?=MmDvV2FPT0WU
EFO-27NHj6OlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXxVZRxUUN3ME2yN{4xPjVzIN88US=>M4jZV3NCVkeHUh?=
NCI-H596MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkThTWM2OD1{Mz64OVI4KM7:TR?=M4r6XHNCVkeHUh?=
KS-1M{OwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfZfYlKSzVyPUK0MlI4PTlizszNNX7zfIlxW0GQR1XS
8305CNXq5SpdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTJ2LkSwOFUh|ryPM3\2NnNCVkeHUh?=
A427NW\pN|lzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3JdZpNUUN3ME2yOU4xOzJ|IN88US=>NVviUoV3W0GQR1XS
COLO-800MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTJ3LkGwOlEh|ryPNUnrUlBRW0GQR1XS
SJRH30M3TqbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXNRVBKSzVyPUK1MlM6ODhizszNNXjLN2wzW0GQR1XS
MEL-HOMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3rQcWlEPTB;MkWuOFMyQSEQvF2=NEPM[FJUSU6JRWK=
FTC-133MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX\MPFZCUUN3ME2yOU45OTh4IN88US=>NXHW[VlnW0GQR1XS
SF295M4i2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NILJbJlKSzVyPUK2MlI6PiEQvF2=NFS5bYpUSU6JRWK=
SW1710NFKyN25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTJ4LkSxNlMh|ryPMWHTRW5ITVJ?
EFM-19NX71UFZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7TXIxvUUN3ME2yOk45OTR3IN88US=>Mmn2V2FPT0WU
NB10M16yd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXP5O|R4UUN3ME2yPE4zOjl5IN88US=>NITpO3BUSU6JRWK=
TK10NIezcnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGPqPJVKSzVyPUK4MlI{QTlizszNNGDHbYlUSU6JRWK=
D-502MGNF;mfmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\LUmlEPTB;MkiuOEDPxE1?M2ftZXNCVkeHUh?=
EW-18NUDsOVRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHNc3d{UUN3ME2yPE41Ozh4IN88US=>MlG0V2FPT0WU
VMRC-RCZMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHLZZo1UUN3ME2yPE46PDFizszNNHzUUZhUSU6JRWK=
Ca9-22M131UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\JVI9KSzVyPUK5MlQ2PTdizszNM3\HbHNCVkeHUh?=
KYSE-70M3zDc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGTLdm5KSzVyPUK5MlU4QDZizszNMn;DV2FPT0WU
A101DNVTsSFJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWXOUmx2UUN3ME2yPU43PDd{IN88US=>NEXJVW9USU6JRWK=
WM-115MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH\x[VFKSzVyPUK5Mlc3ODdizszNMX7TRW5ITVJ?
HCC2157NVfpbHBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHkcWhbUUN3ME2yPU45QDB5IN88US=>NYTTd5FxW0GQR1XS
TE-9NFvEWmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTJ7Lki4OlUh|ryPMlG3V2FPT0WU
K-562MnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUS5T5FHUUN3ME2zNE4xQTN|IN88US=>M4jHbHNCVkeHUh?=
SN12CNUjiblZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnG0TWM2OD1|MD6xOFI3KM7:TR?=MVrTRW5ITVJ?
ESS-1NYm1W4lJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH\ydohKSzVyPUOwMlQ4PTlizszNNV:2TWRvW0GQR1XS
K5NWnRc5M6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4HmTmlEPTB;M{CuO|Y1KM7:TR?=NF3OfphUSU6JRWK=
J82M1v6ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVPvXnJzUUN3ME2zNU4xQDl5IN88US=>MWPTRW5ITVJ?
HOP-92NHH1RnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF7jOm9KSzVyPUOxMlEyOTFizszNMYDTRW5ITVJ?
NCI-H2228NYP1R5I4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFS2c49KSzVyPUOxMlMzQTZizszNNYL3PHFNW0GQR1XS
OCI-AML2NIXtVoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInrSYpKSzVyPUOxMlM3OSEQvF2=NU\aSW1UW0GQR1XS
NCI-SNU-5MonzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmLsTWM2OD1|MT64NVM4KM7:TR?=M1fDRXNCVkeHUh?=
A3-KAWMYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIr6Z2JKSzVyPUOxMlkzPDNizszNNIfLNW9USU6JRWK=
LCLC-103HMkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTN{LkCxO|Eh|ryPMUjTRW5ITVJ?
KY821MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\2SmlEPTB;M{KuOlg5PCEQvF2=NGLVPGxUSU6JRWK=
JVM-2MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\uOmlEPTB;M{KuPVA4QSEQvF2=NH61cGxUSU6JRWK=
Mo-TNGXZU|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn3uTWM2OD1|Mz6xNFA2KM7:TR?=Mnj0V2FPT0WU
IA-LMMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoPrTWM2OD1|Mz6yO|Uh|ryPM4DZZnNCVkeHUh?=
C8166MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{T5U2lEPTB;M{OuN|E6OiEQvF2=NXLQZoZqW0GQR1XS
TCCSUPNHvYZo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTN|LkSzNFch|ryPNHPPTHBUSU6JRWK=
JEG-3NF;rXIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTN|LkS3Olgh|ryPNI\2cY9USU6JRWK=
MS-1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mor3TWM2OD1|Mz61OVUyKM7:TR?=NVrNNVJFW0GQR1XS
NCI-H1304M2LLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3;LPGlEPTB;M{OuOVczPSEQvF2=MYLTRW5ITVJ?
Ramos-2G6-4C10NYH6c5NzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTN2LkCzN|Uh|ryPNVnmUpA2W0GQR1XS
MDA-MB-453NWLWZodNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4rGRWlEPTB;M{SuOlM6PSEQvF2=MVzTRW5ITVJ?
KYSE-520MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTN2LkexPFEh|ryPMkezV2FPT0WU
SW900NFT1fpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3nBSWlEPTB;M{SuPFEyPSEQvF2=MljyV2FPT0WU
HCC2998NW\WRoF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUTXO4RNUUN3ME2zOU4yPTJ7IN88US=>Ml;wV2FPT0WU
A2058M4HTPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jwTmlEPTB;M{WuOlA3OSEQvF2=MnTMV2FPT0WU
OVCAR-3NFu1WnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLGU2hKSzVyPUO2MlIxPDVizszNMU\TRW5ITVJ?
MOLT-4M3P1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NInvbmlKSzVyPUO2MlIzQTRizszNMoDZV2FPT0WU
CAPAN-1M{DVT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4S5W2lEPTB;M{[uOFY6QSEQvF2=NELXRpVUSU6JRWK=
SCC-9MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFTJPY9KSzVyPUO3MlQxOjdizszNNXvBZ45sW0GQR1XS
SF268NXHzWW9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFfzdFlKSzVyPUO4MlM1OzNizszNNYDlRZBiW0GQR1XS
HGC-27MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlLoTWM2OD1|OD6zO|EyKM7:TR?=MVHTRW5ITVJ?
DOHH-2MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljoTWM2OD1|OD63NVU5KM7:TR?=NWDQU41iW0GQR1XS
KE-37MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmH2TWM2OD1|OD65PFI5KM7:TR?=M2Xn[nNCVkeHUh?=
MOLT-13NEe4NYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHOZWRKSzVyPUO5MlI2ODJizszNNVHL[|VoW0GQR1XS
ES1NV;NZpBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\tTWM2OD1|OT6zPFUh|ryPMWLTRW5ITVJ?
SK-OV-3MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEHyW|BKSzVyPUO5Mlk3PDNizszNNX\yfYFlW0GQR1XS
SNU-449NIXlTm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIr0S|JKSzVyPUSwMlA4PjRizszNM4jLT3NCVkeHUh?=
KYSE-510MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M16xfWlEPTB;NECuNVI6PSEQvF2=NX;0NolqW0GQR1XS
HL-60MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTRyLkm3PFMh|ryPNXLhR41nW0GQR1XS
DJM-1M3Xjcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4eyO2lEPTB;NECuPVc6QSEQvF2=NUjFUVA3W0GQR1XS
TGBC11TKBNYiwVJhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUDOSFlkUUN3ME20NU4xQTJ4IN88US=>NX\Mb41TW0GQR1XS
U-2-OSM4[4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLNNpFIUUN3ME20Nk4zPjRzIN88US=>NWPBRXFvW0GQR1XS
NCI-H2030MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTR{LkSzOlgh|ryPM4mwb3NCVkeHUh?=
LU-135MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\lR2lEPTB;NEKuOVQ1PyEQvF2=MoW5V2FPT0WU
ZR-75-30Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{D1dmlEPTB;NEOuNFQ6OyEQvF2=MnTUV2FPT0WU
GT3TKBMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTR|LkK2O|kh|ryPNWSweGpHW0GQR1XS
RPMI-2650MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYi2XZU2UUN3ME20N{44QDF4IN88US=>M2rldXNCVkeHUh?=
SASNEn5VFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWjCdnp1UUN3ME20N{46PTN2IN88US=>MX3TRW5ITVJ?
MDA-MB-231M1fTfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTR|Lkm2NFkh|ryPM3nJdXNCVkeHUh?=
JVM-3MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGO0[3FKSzVyPUS0MlA2OzNizszNMlTVV2FPT0WU
COLO-320-HSRNVi1fW1xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTR2LkW2N|Mh|ryPNHzr[VNUSU6JRWK=
SNB75MorJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mmf3TWM2OD12ND62NVA2KM7:TR?=NXPT[GJLW0GQR1XS
NCI-H441M{PpWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXrvPG83UUN3ME20OE46OzJ6IN88US=>M37WOXNCVkeHUh?=
HCT-116MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTR2Lkm4Olgh|ryPMnPJV2FPT0WU
NCI-H226MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVvCeo5XUUN3ME20OU43OzZ6IN88US=>NVzsR3dRW0GQR1XS
CAL-33M1nYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvaR3NKSzVyPUS1MlkzOTdizszNNE\le3ZUSU6JRWK=
NCI-H1437M4rRW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmTaTWM2OD12Nj6zNlEh|ryPMnX4V2FPT0WU
HCC1187NUPmcpU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUPhOllSUUN3ME20Ok41OjV3IN88US=>NX7C[VVmW0GQR1XS
NUGC-3Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTR4LkW3NFkh|ryPM2HJNHNCVkeHUh?=
T98GNVj5bJJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXvHVYdrUUN3ME20O{42PDdizszNM1jqV3NCVkeHUh?=
OVCAR-8M1LqV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXrJR|UxRTR5Lk[4N{DPxE1?MYXTRW5ITVJ?
LB2241-RCCMnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmWxTWM2OD12Nz63Nlch|ryPMkjxV2FPT0WU
NCI-H358Mk\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEW5UFVKSzVyPUS4MlEyPTJizszNMVjTRW5ITVJ?
PANC-08-13M4r5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3q1dmlEPTB;NEiuNVg2OyEQvF2=MWrTRW5ITVJ?
KP-N-YNM2DQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYPJR|UxRTR6LkKxNFIh|ryPNHTo[JVUSU6JRWK=
NCI-H1755MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFWxcGxKSzVyPUS4MlI4OjZizszNMlnYV2FPT0WU
NCI-N87NUfCTIZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYnMNldPUUN3ME20PE4zQTlzIN88US=>NHS2cW1USU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Administration of PD173074 at 1 mg/kg/day or 2 mg/ka/day in mice can effectively block angiogenesis induced by either FGF or VEGF in a dose-dependent manner with no apparent toxicity. [1] PD173074 inhibits in vivo growth of mutant FGFR3-transfected NIH 3T3 cells in nude mice. Inhibition of FGFR3 by PD173074 delays tumor growth and increases survival of mice in a KMS11 xenograft myeloma model. [4] In the H-510 xenograft, oral aministration of PD173074 blocks tumor growth similar to that seen with single-agent cisplatin administration, increasing median survival compared with control sham-treated animals. In H-69 xenografts, PD173074 induces complete responses lasting >6 months in 50% of mice. These effects are correlated with increased apoptosis in excised tumors, but not a consequence of disrupted tumor vasculature. [5]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

In vitro kinase inhibition assays Assays using the full-length FGFR-1 kinase are performed in a total volume of 100 μL containing 25 mM HEPES buffer (pH 7.4), 150 mM NaCl, 10 mM MnCl2, 0.2 mM sodium orthovanadate, 750 μg/mL concentration of a random copolymer of glutamic acid and tyrosine (4:1), various concentrations of PD173074 and 60 to 75 ng of enzyme. The reaction is initiated by the addition of [γ-32P]ATP (5 μM ATP containing 0.4 μCi of [γ-32P]ATP per incubation), and samples are incubated at 25°C for 10 minutes. The reaction is terminated by the addition of 30% trichloroacetic acid and the precipitation of material onto glass-fiber filter mats. Filters are washed three times with 15% trichloroacetic acid, and the incorporation of [32P] into the glutamate tyrosine polymer substrate is determined by counting the radioactivity retained on the filters in a Wallac 1250 betaplate reader. Nonspecific activity is defined as radioactivity retained on the filters following incubation of samples without enzyme. Specific activity is determined as total activity (enzyme plus buffer) minus nonspecific activity. The concentration of PD173074 that inhibits FGFR-1 enzymatic activity by 50% (IC50) is determined graphically.

Cell Assay: [4]

Cell lines KMS11 and KMS18
Concentrations Dissolved in DMSO, final concentrations ~100 nM
Incubation Time 48 hours
Method Cells are incubated with increasing concentrations of PD173074 in the presence of aFGF/heparin for 48 hours. The percentage of viable cells is determined by MTT.

Animal Study: [1]

Animal Models Swiss Webster mice with induced corneal angiogenesis
Formulation Prepared in sterile fashion
Dosages ~2 mg/kg/day
Administration Administered intraperitoneally

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Mohammadi M, et al. EMBO J, 1998, 17(20), 5896-5904.

[2] Skaper SD, et al. J Neurochem, 2000, 75(4), 1520-1527.

view more

Chemical Information

Download PD173074 SDF
Molecular Weight (MW) 523.67
Formula

C28H41N7O3

CAS No. 219580-11-7
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 100 mg/mL (190.95 mM)
Ethanol 100 mg/mL (190.95 mM)
Water <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 1-tert-butyl-3-(2-(4-(diethylamino)butylamino)-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea

Customer Product Validation(6)


Click to enlarge
Rating
Source Science 2011 331(6019), 912-6. PD173074 purchased from Selleck
Method Immunohistochemistry
Cell Lines uterine horn
Concentrations
Incubation Time
Results The epithelia of vehicle-treated horn showed prominent expression of p-FRS2 and p-ERK1/2 (Fig. A, a and c). However, the levels of both p-FRS2 and p-ERK1/2 were reduced in the epithelia of PD173074-treated horn on day 4 of pregnancy (Fig. A, b and d). We also observed a marked decline in the proliferative activity of Hand2-null uterine epithelia, as indicated by decreased Ki-67 staining (Fig. A, e and f). Administration of either PD173074 (Fig. C, a to d) or PD184352 (Fig. C, e to h) to Hand2-null uterine horns blocked the phosphorylation of epithelial ER a at Ser118 and the expression of Muc-1.

Click to enlarge
Rating
Source Cancer Discov 2013 3(6), 636-47. PD173074 purchased from Selleck
Method Western blot
Cell Lines SW780 cells
Concentrations 10, 40 mg/kg
Incubation Time
Results Similar results for FGFR fusion-positive lines were obtained in vivo. SW780 xenografts exhibited decreased tumor growth with increasing doses of PD173074.

Click to enlarge
Rating
Source Hepatology 2014 59(4) ,1427-34. PD173074 purchased from Selleck
Method Western blot
Cell Lines NIH3T3 cells
Concentrations 0.2, 1 uM
Incubation Time 2 h
Results It examined the sensitivity of FGFR2 fusion-driven tumor cells to two specific FGFR inhibitors, BGJ398 and PD173074, which selectively inhibit FGFR tyrosine kinase activity. PD173074 significantly inhibited the phosphorylation of MAPK and reduced in vitro anchorage-independent colony formation to the level observed in KD mutant expressing cells.

Click to enlarge
Rating
Source PLoS Genet 2012 8(2), e1002500. PD173074 purchased from Selleck
Method Immunohistochemistry
Cell Lines Msx1d/dMsx2d/d mice
Concentrations 50 uM
Incubation Time 24 h
Results PD173074, a FGFR-specific inhibitor, or vehicle into uterine horns of Msx1d/dMsx2d/d mice in the pre-implantation phase. As shown in Figure, the epithelia of vehicle-treated uterine horns of these mice showed strong expression of phospho-FRS2 on day 4 of pregnancy (panel a). Treatment with the PD173074 led to a marked reduction in the level of phospho-FRS2 in the uterine epithelium (panel b). Concomitant with this down regulation of FGFR signaling, it observed a decline in the proliferative activity of Msx1Msx2-null uterine epithelia as well as down-regulation of MUC-1 expression (panels c–f).

Click to enlarge
Rating
Source Biochem Bioph Res Co 2012 11(9), 745-57. PD173074 purchased from Selleck
Method Western Blot
Cell Lines 293MSR-GT
Concentrations 15 uM
Incubation Time 48 h
Results we noticed that inhibition of activity of several receptor Tyr kinases (RTKs) (or of their downstream signaling), especially the FGFRs, with small molecules (e.g. SU5402, SU6668, PD173074, EKI-785/CL-387,785, Ki8751) led to a robust rescue of DF508-CFTR (Fig. 1).

Click to enlarge
Rating
Source J Cell Sci 2014 10.1242/jcs.159608. PD173074 purchased from Selleck
Method Real time microscopy
Cell Lines GFP-MPR cells
Concentrations 10 uM
Incubation Time 1 h
Results Incubation with the FGFR inhibitor PD173074 for 1h caused the fragmentation of the perinuclear GFP-MPR compartment (91?4% of the cells, mean ?s.d., n = 3 experiments) , thus mimicking FGFR1 knockdown.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related FGFR Products

  • CH5183284 (Debio-1347)

    CH5183284 is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. Phase 1.

  • BLU9931

    BLU9931 is a potent, selective, and irreversible FGFR4 inhibitor with IC50 of 3 nM, about 297-, 184-, and 50-fold selectivity over FGFR1/2/3, respectively.

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • BGJ398 (NVP-BGJ398)

    BGJ398 (NVP-BGJ398) is a potent and selective FGFR inhibitor for FGFR1/2/3 with IC50 of 0.9 nM/1.4 nM/1 nM in cell-free assays, >40-fold selective for FGFR versus FGFR4 and VEGFR2, and little activity to Abl, Fyn, Kit, Lck, Lyn and Yes. Phase 2.

  • AZD4547

    AZD4547 is a novel selective FGFR inhibitor targeting FGFR1/2/3 with IC50 of 0.2 nM/2.5 nM/1.8 nM in cell-free assays, weaker activity against FGFR4, VEGFR2(KDR), and little activity observed against IGFR, CDK2, and p38. Phase 2/3.

    Features:Greater selectivity for FGFR1-3 over FGFR4. AZD4547 is active against the tyrosine kinase activity of both the wild-type and mutant forms of FGFR.

  • SSR128129E

    SSR128129E is an orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.

  • LY2874455

    LY2874455 is a pan-FGFR inhibitor with IC50 of 2.8 nM, 2.6 nM, 6.4 nM, and 6 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively, and also inhibits VEGFR2 activity with IC50 of 7 nM. Phase 1.

  • Ibrutinib (PCI-32765)

    Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

  • Dasatinib

    Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

  • Saracatinib (AZD0530)

    Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.

    Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

Recently Viewed Items

Tags: buy PD173074 | PD173074 supplier | purchase PD173074 | PD173074 cost | PD173074 manufacturer | order PD173074 | PD173074 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us